Short-term testosterone augmentation in male schizophrenics

A randomized, double-blind, placebo-controlled trial

Young-Hoon Ko, Young Min Lew, Sung Won Jung, Sook Haeng Joe, Chang Hyun Lee, Hyun-Ghang Jeong, Moon-Soo Lee

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Although there are few studies on the treatment of schizophrenia with testosterone, several indirect findings have suggested testosterone as a possible treatment modality for schizophrenia. To explore the therapeutic effect of testosterone augmentation of antipsychotic medication on symptoms in male patients with schizophrenia, the authors performed a placebo-controlled, double-blind trial on 30 schizophrenic men, using either 5 g of 1% testosterone gel (Testogel; Besins Iscovesco, Paris, France) or a placebo added to a fixed dosage of antipsychotic medication over a period of 4 weeks with a 2-week washout period. In addition, to get additional information about the involvement of these reproductive hormones after testosterone augmentation, the authors evaluated several hormones such as total testosterone, free testosterone, dehydroepiandrosterone sulfate, estradiol, and prolactin. Results indicated a significant improvement of negative symptoms in both the last observation carried forward and the completer analyses and a nonsignificant trend for the improvement of depressive symptoms in completers. There were no significant changes in serum hormone levels except total and free testosterone. The findings of this study suggest that testosterone augmentation may be a potential therapeutic strategy in patients with schizophrenia.

Original languageEnglish
Pages (from-to)375-383
Number of pages9
JournalJournal of Clinical Psychopharmacology
Volume28
Issue number4
DOIs
Publication statusPublished - 2008 Aug 1

Fingerprint

Testosterone
Placebos
Schizophrenia
Hormones
Antipsychotic Agents
Dehydroepiandrosterone Sulfate
Paris
Therapeutic Uses
Prolactin
France
Estradiol
Therapeutics
Gels
Observation
Depression
Serum

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Short-term testosterone augmentation in male schizophrenics : A randomized, double-blind, placebo-controlled trial. / Ko, Young-Hoon; Lew, Young Min; Jung, Sung Won; Joe, Sook Haeng; Lee, Chang Hyun; Jeong, Hyun-Ghang; Lee, Moon-Soo.

In: Journal of Clinical Psychopharmacology, Vol. 28, No. 4, 01.08.2008, p. 375-383.

Research output: Contribution to journalArticle

@article{77850d45de314ceeb32b1a3917e8024a,
title = "Short-term testosterone augmentation in male schizophrenics: A randomized, double-blind, placebo-controlled trial",
abstract = "Although there are few studies on the treatment of schizophrenia with testosterone, several indirect findings have suggested testosterone as a possible treatment modality for schizophrenia. To explore the therapeutic effect of testosterone augmentation of antipsychotic medication on symptoms in male patients with schizophrenia, the authors performed a placebo-controlled, double-blind trial on 30 schizophrenic men, using either 5 g of 1{\%} testosterone gel (Testogel; Besins Iscovesco, Paris, France) or a placebo added to a fixed dosage of antipsychotic medication over a period of 4 weeks with a 2-week washout period. In addition, to get additional information about the involvement of these reproductive hormones after testosterone augmentation, the authors evaluated several hormones such as total testosterone, free testosterone, dehydroepiandrosterone sulfate, estradiol, and prolactin. Results indicated a significant improvement of negative symptoms in both the last observation carried forward and the completer analyses and a nonsignificant trend for the improvement of depressive symptoms in completers. There were no significant changes in serum hormone levels except total and free testosterone. The findings of this study suggest that testosterone augmentation may be a potential therapeutic strategy in patients with schizophrenia.",
author = "Young-Hoon Ko and Lew, {Young Min} and Jung, {Sung Won} and Joe, {Sook Haeng} and Lee, {Chang Hyun} and Hyun-Ghang Jeong and Moon-Soo Lee",
year = "2008",
month = "8",
day = "1",
doi = "10.1097/JCP.0b013e31817d5912",
language = "English",
volume = "28",
pages = "375--383",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Short-term testosterone augmentation in male schizophrenics

T2 - A randomized, double-blind, placebo-controlled trial

AU - Ko, Young-Hoon

AU - Lew, Young Min

AU - Jung, Sung Won

AU - Joe, Sook Haeng

AU - Lee, Chang Hyun

AU - Jeong, Hyun-Ghang

AU - Lee, Moon-Soo

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Although there are few studies on the treatment of schizophrenia with testosterone, several indirect findings have suggested testosterone as a possible treatment modality for schizophrenia. To explore the therapeutic effect of testosterone augmentation of antipsychotic medication on symptoms in male patients with schizophrenia, the authors performed a placebo-controlled, double-blind trial on 30 schizophrenic men, using either 5 g of 1% testosterone gel (Testogel; Besins Iscovesco, Paris, France) or a placebo added to a fixed dosage of antipsychotic medication over a period of 4 weeks with a 2-week washout period. In addition, to get additional information about the involvement of these reproductive hormones after testosterone augmentation, the authors evaluated several hormones such as total testosterone, free testosterone, dehydroepiandrosterone sulfate, estradiol, and prolactin. Results indicated a significant improvement of negative symptoms in both the last observation carried forward and the completer analyses and a nonsignificant trend for the improvement of depressive symptoms in completers. There were no significant changes in serum hormone levels except total and free testosterone. The findings of this study suggest that testosterone augmentation may be a potential therapeutic strategy in patients with schizophrenia.

AB - Although there are few studies on the treatment of schizophrenia with testosterone, several indirect findings have suggested testosterone as a possible treatment modality for schizophrenia. To explore the therapeutic effect of testosterone augmentation of antipsychotic medication on symptoms in male patients with schizophrenia, the authors performed a placebo-controlled, double-blind trial on 30 schizophrenic men, using either 5 g of 1% testosterone gel (Testogel; Besins Iscovesco, Paris, France) or a placebo added to a fixed dosage of antipsychotic medication over a period of 4 weeks with a 2-week washout period. In addition, to get additional information about the involvement of these reproductive hormones after testosterone augmentation, the authors evaluated several hormones such as total testosterone, free testosterone, dehydroepiandrosterone sulfate, estradiol, and prolactin. Results indicated a significant improvement of negative symptoms in both the last observation carried forward and the completer analyses and a nonsignificant trend for the improvement of depressive symptoms in completers. There were no significant changes in serum hormone levels except total and free testosterone. The findings of this study suggest that testosterone augmentation may be a potential therapeutic strategy in patients with schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=54449085337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54449085337&partnerID=8YFLogxK

U2 - 10.1097/JCP.0b013e31817d5912

DO - 10.1097/JCP.0b013e31817d5912

M3 - Article

VL - 28

SP - 375

EP - 383

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 4

ER -